Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$116.32 USD
+4.62 (4.14%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $116.30 -0.02 (-0.02%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Blueprint Medicines (BPMC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$118.00 | $168.00 | $75.00 | 5.64% |
Price Target
Based on short-term price targets offered by 16 analysts, the average price target for Blueprint Medicines comes to $118.00. The forecasts range from a low of $75.00 to a high of $168.00. The average price target represents an increase of 6.92% from the last closing price of $110.36.
Analyst Price Targets (16)
Broker Rating
Blueprint Medicines currently has an average brokerage recommendation (ABR) of 1.76 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 17 brokerage firms. The current ABR compares to an ABR of 1.76 a month ago based on 17 recommendations.
Of the 17 recommendations deriving the current ABR, 11 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 64.71% and 5.88% of all recommendations. A month ago, Strong Buy made up 64.71%, while Buy represented 5.88%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/BPMC.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 11 | 10 | 10 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 4 | 4 | 4 | 4 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 2 |
ABR | 1.76 | 1.76 | 1.76 | 1.81 | 1.94 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/14/2024 | Stephens | Sudan Loganathan | Not Available | Strong Buy |
5/6/2024 | SVB Securities | Andrew Berens | Strong Sell | Hold |
5/6/2024 | Goldman Sachs | Salveen Richter | Strong Buy | Strong Buy |
5/3/2024 | Wells Fargo Securities | Derek C Archila | Strong Buy | Strong Buy |
5/3/2024 | Not Identified | Not Identified | Hold | Hold |
5/3/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
5/3/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/26/2024 | Needham & Company | Ami Fadia | Moderate Buy | Moderate Buy |
4/26/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
4/26/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
4/25/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/22/2024 | Piper Sandler | Christopher Raymond | Hold | Hold |
4/10/2024 | JMP Securities | Reni Benjamin | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Marc Frahm | Strong Buy | Strong Buy |
2/29/2024 | Guggenheim Securities | Michael Schmidt | Strong Buy | Strong Buy |
10/28/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.76 |
ABR (Last week) | 1.76 |
# of Recs in ABR | 17 |
Average Target Price | $118.00 |
LT Growth Rate | 34.00% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 252 |
Current Quarter EPS Est: | -1.30 |